Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Oct;42(5):1118-22.
doi: 10.1177/0300060514539280. Epub 2014 Aug 20.

Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis

Affiliations
Free article
Randomized Controlled Trial

Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis

Cenk Akçali et al. J Int Med Res. 2014 Oct.
Free article

Abstract

Objective: A prospective, randomized clinical study to compare the short-term effects of cyclosporin and acitretin on psoriasis severity, and serum interleukin (IL)-2 and tumour necrosis factor (TNF)-α concentrations.

Methods: Patients with moderate-to-severe plaque-type psoriasis were randomly assigned to receive either 3 mg/kg per day cyclosporine or 0.3-0.5 mg/kg per day acitretin for 8 weeks. Disease severity (psoriasis area severity index [PASI] score) and serum IL-2 and TNF-α concentrations were determined before and after treatment.

Results: PASI scores and serum IL-2 and TNF-α concentrations were significantly decreased after treatment with either cyclosporine (n = 21) or acitretin (n = 25). There were no statistically significant between-group differences in any parameter.

Conclusions: Acitretin and cyclosporine are equally effective in the treatment of moderate-to-severe plaque-type psoriasis.

Keywords: Psoriasis; acitretin; cyclosporine; interleukin-2 (IL-2); tumour necrosis factor-α (TNF-α).

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources